Today: 10 June 2026
Strategy Inc stock jumps nearly 9% on bitcoin rebound; STRC treasury buyers add a new angle
26 February 2026
1 min read

Strategy Inc stock jumps nearly 9% on bitcoin rebound; STRC treasury buyers add a new angle

New York, Feb 25, 2026, 6:01 PM EST — After-hours

  • Strategy (MSTR) finished up 8.9%, but slipped roughly 1% in after-hours moves
  • Bitcoin jumped roughly 6.7% to trade near $68,400, sending crypto-related stocks higher.
  • Strategy offloaded shares in a recent filing, putting the cash toward additional bitcoin purchases.

Strategy Inc surged 8.9% to finish at $135.65 on Wednesday, fueled by bitcoin’s strong bounce that lured buyers to a stock often seen as a liquid bitcoin proxy. Shares later slipped roughly 1% in after-hours action.

Bitcoin climbed 6.7% to trade near $68,400, a session that saw prices range from around $63,900 up to almost $69,800 earlier this day.

This shift is notable: Strategy’s equity has basically turned into a high-beta proxy for bitcoin exposure among U.S. stocks. Traders are still weighing how a more stable crypto backdrop might shape the company’s next funding moves.

Strategy unloaded 297,940 Class A shares in an at-the-market offering, raking in $39.7 million, according to a Feb. 23 filing. The company turned around and plowed those proceeds into 592 bitcoin at an average price of $67,286 each. As of Feb. 22, Strategy reported holding 717,722 bitcoin, acquired at a total cost of roughly $54.56 billion, or an average of $76,020 per coin.

Strategy, in a statement Wednesday, reported that Prevalon Energy and Anchorage Digital revealed at Strategy World 2026 that both had allocated a portion of their corporate treasury to STRC, the variable-rate preferred stock issued by Strategy. Chief Executive Phong Le described STRC as the company’s “flagship digital credit instrument,” highlighting its 11.25% annual dividend, paid out monthly, and a structure aimed at “stable price dynamics.” Business Wire

Shares of crypto-exposed firms tracked the token’s action, with Coinbase Global jumping 13.5% for the session, Finviz data showed.

Reuters’ “Trading Day” column on Wednesday caught a broader chase for battered names—tech stocks, precious metals, even bitcoin—as buyers drifted back toward risk following two days of equity gains. Reuters

Even so, Strategy’s approach isn’t without tradeoffs. The company’s bitcoin purchases have leaned heavily on frequent capital raises; issuing more equity can drag down per-share value, even if bitcoin itself is climbing.

The stock doesn’t just track bitcoin; it often leaves the crypto behind, both on the way up and down. If bitcoin plunges, Strategy’s shares usually exaggerate the drop. That kind of swing can punish investors who jump in late, especially if the crypto recovery doesn’t hold.

The focus shifts to Las Vegas as Strategy World 2026 continues through Feb. 26. Bitcoin treasury plans and “digital credit” dominate the program, with investors zeroed in on any fresh details around Strategy’s funding mechanisms or how quickly it’s stacking bitcoin. Business Wire

Stock Market Today

  • Palantir Technologies (PLTR) Shares Seen Fairly Valued Amid Recent Decline
    June 10, 2026, 5:48 PM EDT. Palantir Technologies has seen its share price fall 13.2% over the past week and 21.3% year to date, following extraordinary gains in prior years. At $132.07 per share, Palantir trades slightly below its estimated intrinsic value of $145.11 based on a Discounted Cash Flow (DCF) analysis, suggesting a modest 9% discount. The company posted $2.69 billion in free cash flow over the past twelve months, with projections rising to $16.11 billion by 2030. Despite recent volatility tied to sentiment on artificial intelligence and software spending, Palantir remains fairly valued but not a clear bargain. Investors should monitor further market developments and valuation metrics to gauge future opportunities or risks.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Microsoft stock price rebounds as Japan raids Azure unit; MSFT investors eye Nvidia earnings
Previous Story

Microsoft stock price rebounds as Japan raids Azure unit; MSFT investors eye Nvidia earnings

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus
Next Story

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Go toTop